EDGEMOND JAMES sold $5.5M of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 10,000 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $549.29 ($542.94–$551.82, $5.49M total) across 9 trades on 2026-06-11 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a concrete, dated insider selling event, but it does not include any new operational, regulatory, or financial catalyst for United Therapeutics.
Market read
Useful for monitoring insider behavior and sentiment, but not a standalone fundamental catalyst.
What to watch
Traders may focus on the sale size, but the key nuance is that the transaction is spread across multiple prints and executed under a plan, which often aligns with routine liquidity rather than a directional view.
Background
The article is an SEC Form 4 insider transaction disclosure (open-market sale) for United Therapeutics’ CFO/Treasurer.
Ticker impact
SEC Form 4 shows UTHR CFO/Treasurer Edgemond James sold 10,000 shares in an open-market transaction under a 10b5-1 plan.
Likely limited/short-lived impact; watch for follow-through only if other insiders or fundamentals change.
The filing is a primary-source insider transaction with defined execution details, but it does not disclose new company fundamentals; 10b5-1 reduces interpretive weight.
Market effects
No direct sector read-across; this is company-specific insider activity.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, the market may overreact; price impact may be negligible once traders recognize the plan structure.
Key entities
- issuerUnited Therapeutics Corp
Subject of the SEC Form 4 insider transaction disclosure.
- insiderEdgemond James
CFO and Treasurer who sold shares under a Rule 10b5-1 plan.
